• site map

• text size: A- | A+

• : . view text-only
• : . view graphic version

• Research Home
• Neurosciences
• Environmental Toxicology
• Cardiovascular Pharmacology
• Medicinal Chemistry
• Pharmocogenetics
• Cancer Research
• Centers and Facilities

Neuroscience

Small molecule and biochemical approaches to solving neuroscience problems in Alzheimer’s, Parkinson’s, CNS neoplasms, Acute/chronic neurotoxicity, depression, DNA repair, Air pollution neurotoxicity, design and synthesis of neurotransmitters, receptors, and precursors, synthesis of inhibitors, gene therapy, GPCR function in neurological disorders, development and regeneration of nervous system, anti-migraine drugs, glutamine, glutamate transporters, organophosphate neurotoxicity, action of cannabinoids

C. Sean Esslinger, Research Associate Professor; Ph.D. (organic chemistry), Colorado State, 1992. Design and asymmetric synthesis of neurotransmitter and neurotransmitter precursor analogues, molecular modeling, neuroscience tool development.

David J. Poulsen, Research Associate Professor; Ph.D. (molecular virology), Delaware, 1995. Gene therapy of the CNS and auditory system.

J. Josh Lawrence, Assistant Professor, Ph.D. (neuroscience), University of Wisconsin-Madison, 1999.  Organizing principles governing neuromodulation of GABAergic inhibition.

Erica L. Woodahl, Assistant Professor, Ph.D. (pharmaceutics), University of Washington, 2004.  Pharmacogenomics of drug transporters and drug-metabolizing enzymes in drug response, toxicity, and disease susceptibility.

Lilian Calderón-Garcidueñas, Associate Professor; M.D., Ph.D. (toxicology), North Carolina, 2001. Chronic health effects of air pollution in the respiratory, cardiovascular and central nervous systems.

Fernando Cardozo-Pelaez, Associate Professor; Ph.D. (medical sciences), South Florida, 1996. The effect of environmental neurotoxins on DNA damage, DNA repair capacity, and neuronal function in the CNS.

Darrell A. Jackson, Associate Professor; Ph.D. (pharmacology/toxicology), Washington State, 1990. G-protein-coupled receptor signaling in neurological disorders including Alzheimer's disease, Parkinson's disease, and stroke.

Keith K. Parker, Associate Professor; Ph.D. (pharmacology), California, San Francisco, 1977. Neurochemistry and molecular neuropharmacology, particularly the development of new anti-migraine drugs and studies of serotonin receptor-G protein interactions.

Richard J. Bridges, Professor; Ph.D. (biochemistry), Cornell, 1984. Pharmacology and toxicology related to excitatory amino acid transporters, receptors and glutamate-mediated neuropathology.

Diana I. Lurie, Professor; Ph.D. (neuroscience), Pennsylvania, 1989. Development and regeneration of the nervous system. The effect of toxins such as lead on CNS development and the neural and glial response to injury.

Michael P. Kavanaugh, Professor; Ph.D. (biochemistry), Oregon Health Sciences, 1986. Neurotransmitter transport and synaptic physiology; neuronal signaling, mechanisms of learning and memory.

Nicholas Natale, Professor; Ph.D. (organic chemistry), Drexel University, 1979. Isoxazoles in medicinal chemistry, especially applied towards potential anti-hypertensive anti-cancer and Alzheimer's therapeutics.

Charles M. Thompson, Professor; Ph.D. (organic chemistry), California, Riverside, 1982. Medicinal and bioorganic chemistry, neurochemistry; synthesis of novel small molecule probes of protein structure and function; protein mass spectrometry and proteomics; oragnophosphorus inhibitors; pharmacophore development.

Charles L. Eyer, Professor Emeritus; Ph.D. (pharmacology), Washington State, 1976. Oxidative damage, metal neurotoxicity, cellular responses to stress.